Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersAna M. Aparicio, Christopher J. Logothetis, Li Shen et al.|Clinical Cancer Research|2015Cited by 297
A comprehensive molecular characterization of aggressive variant prostate cancer (PC).Ana M. Aparicio, Sankar N. Maity, Li Shen et al.|Journal of Clinical Oncology|2015Cited by 2
Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX).Ana M. Aparicio, Sankar N. Maity, Li Shen et al.|Journal of Clinical Oncology|2015Cited by 1
AVPC Molecular Signature Supplementary Figures from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersAna M. Aparicio, Christopher J. Logothetis, Li Shen et al.|Unknown|2023Cited by 0
AVPC Molecular Signature Aparicio Supplementary Material from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersAna M. Aparicio, Christopher J. Logothetis, Li Shen et al.|Unknown|2023Cited by 0